

Puma Biotechnology

Earnings Call

Commercial Update



May 9, 2019


nerlynx[®]
(neratinib) tablets




Forward-Looking Safe Harbor Statement

This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX®. All statements other than historical facts are forward-looking statements and are based on the current expectations, forecasts and assumptions of Puma Biotechnology, Inc. (“Puma”). Forward-looking statements involve risks and uncertainties that could cause Puma’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These risk and uncertainties are identified in Puma’s Annual Report on Form 10-K for the year ended December 31, 2018 and any subsequent documents Puma files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and you should not rely on these forward-looking statements as representing Puma’s views as of any date subsequent to the date of this presentation. Puma assumes no obligation to update these forward-looking statements, except as required by law.


Puma's Pharmacy and Distributor Network



\$45.6 Million Net Revenue in Q1 2019



Bottles Sold By Quarter




• *SP = Specialty Pharmacy Network, SD = Specialty Distributor Network*




Time to First Dispense in Specialty Pharmacy Network

PERCENT OF PATIENTS TIME TO FIRST DISPENSE



74% of patients receive their first dispense within 15 days of a network SP receiving the RX

74% of Targeted Prescribers Reached



- Reach defined as physician detailed.
- Numbers reported for historical quarters may be slightly different from previous statements due to data updates

Pierre Fabre License for NERLYNX[®] in Europe

March 2019



Pierre Fabre

- Well established oncology commercial/medical infrastructure in breast cancer throughout Europe, based on Navelbine[®] (vinorelbine)
- Pierre Fabre has commercial and development rights to neratinib in Europe and parts of North and Western Africa
- First anticipated launch is Germany in 2019, with other countries to follow in 2019/2020
- UK NICE submission complete and under review
- Major financial terms of the agreement
 - \$60M USD upfront upon execution of the license agreement
 - Additional commercial and regulatory milestones totaling \$345M USD
 - Double digit royalties up to 40% on net sales

Rest of World Partnerships – Timelines

Region	Partner	Expected Regulatory Approval
Australia / SE Asia	 Specialised Therapeutics	<ul style="list-style-type: none"> Approved in ITT population – Australia
Israel	 MEDISON <small>Delivering Innovative Healthcare</small>	<ul style="list-style-type: none"> Q3 2019
Canada	 Knight	<ul style="list-style-type: none"> Q3 2019
Greater China	 CANbridge 北 海 康 成	<ul style="list-style-type: none"> 1H 2020 – China Q4 2019 – Hong Kong 1H 2020 – Taiwan
Latin America South America	 PINT PHARMA	<ul style="list-style-type: none"> 1H 2020 – Mexico 1H 2020 – Argentina 1H 2020 – Chile 1H 2020 – Ecuador 1H 2020 – Peru 2H 2020 – Colombia 1H 2021 – Brazil

Puma Biotechnology

Earnings Call

Commercial Update



May 9, 2019

nerlynx[®]
(neratinib) tablets